{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.3","upperLimit":"82.2","value":"73.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"}],"units":"Participants"}],"description":"Progression-free survival of participants that received tandem transplants on study","dispersionType":"95% Confidence Interval","groups":[{"description":"Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma\n\nBortezomib: Bortezomib 1.6mg/m2 on day -4 and day -1","id":"OG000","title":"Tandem Transplantation With Melphalan and Bortezomib"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"To Determine the Progression-free Survival of Patients With Multiple Myeloma Treated With Tandem Cycles of High-dose Melphalan Followed by High-dose Melphalan in Combination With Bortezomib With Autologous HSC Transplantation.","type":"PRIMARY","unitOfMeasure":"Percent"}